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Abstract
Introduction: High-intensity focused ultrasound (HIFU) is an ablative treatment undergoing assessment for the
treatment of benign and malignant disease. We describe the first reported intracavitary HIFU ablation for recurrent,
unresectable and symptomatic cervical cancer.
Case description: A 38 year old woman receiving palliative chemotherapy for metastatic cervical adenocarcinoma
was offered ablative treatment from an intracavitary trans-rectal HIFU device (Sonablate® 500). Pre-treatment
symptoms included vaginal bleeding and discharge that were sufficient to impede her quality of life. No peri-
procedural adverse events occurred. Symptoms resolved completely immediately post-procedure, reappeared at
7 days, increasing to pre-procedural levels by day 30.
Discussion and evaluation: This first time experience of intracavitary cervical HIFU suggests that it is feasible for
palliation of advanced cervical cancer, with no early evidence of unexpected toxicity. Ethical approval had also been
granted for the use of per-vaginal access if appropriate. This route, alone or in combination with the rectal route, may
provide increased accessibility in future patients with a redesigned device more suited to trans-vaginal ablations.
Conclusion: Intracavitary HIFU is a potentially safe procedure for the treatment of cervical cancer and able to provide
symptomatic improvement in the palliative setting.
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Background
High-intensity focused ultrasound (HIFU) is a non-
invasive ablative treatment undergoing assessment for
the treatment of benign and malignant disease with en-
couraging results. As technology advances and expertise
accumulates, previous limiting factors including image-
guidance (to accurately identify, target and monitor
treatment) and lengthy therapeutic duration are being
overcome. We describe the first reported intracavitary
HIFU ablation for cervical cancer and determine that
HIFU was feasible with demonstrable benefits.
Cervical cancer is the fourth most common cancer in
women worldwide, with an estimated incidence of ap-
proximately 528,000 diagnoses and 266,000 deaths annu-
ally [1]. It is potentially curable with a multi-modal
approach that may include surgical excision, radio-
therapy and cytotoxic chemotherapy. These therapeutic
modalities may also delay progression and improve
symptom control in advanced disease by palliating the
unpleasant symptoms that include vaginal bleeding and/
or discharge and intractable pain which can all impact
negatively on quality of life.
HIFU conveys sonic energy to a defined target raising
temperature to cause cell death by coagulative necrosis.
Single-element devices consist of a curved transducer or
incorporate lens to focus the energy at the target site.
Ultrasonic waves from multi-element arrays converge at
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the treatment zone to cause ablation. Intervening tissues
remain completely unharmed. Ablations are sequentially
repeated in adjacent pathological tissue until the desired
volume is destroyed. Guidance and monitoring of the
treatment is through integrated ultrasound or magnetic
resonance imaging [2].
HIFU devices are either intracavitary (minimally inva-
sive through insertion into rectum or vagina) or extracor-
poreal (completely non-invasive). Intracavitary devices in
the rectum have been extensively studied in thousands of
men with prostate cancer [3], but to date, there has been
no report of intracavitary HIFU in cervical cancer. Extra-
corporeal HIFU has been reported in one woman with
cervical cancer successfully palliating local pain [4]. In the
past, lengthy treatment times and difficulties with accur-
acy of targeting have prevented wide-spread HIFU use, al-
though current technology is rapidly improving to
overcome these limitations.
UK National Ethics Committee approval (09/H0808/43)
was granted for a pilot study to assess the feasibility, safety
and efficacy of ultrasound-guided intracavitary HIFU in
pelvic malignancy. Intracavitary HIFU treatment of a man
with recurrent anastomotic colorectal cancer by our group
resulted in symptomatic improvement within 24 h and
radiological evidence of tumour necrosis at the target ab-
lation site [5]. We wanted to expand the potential of intra-
cavitary HIFU therapy by, for the first time, determining
feasibility for its use and ability to palliate, relieve pain and
improve quality of life in advanced cervical cancer.
Case presentation
A 38 year old woman presenting with stage 1B2 histo-
logically confirmed cervical adenocarcinoma and re-
ceived primary chemotherapy/radiation followed by a
brachytherapy boost. Ten months later, a recurrent local
cervical mass and small volume nodal and pulmonary
disease were identified radiologically. Palliative carbopla-
tin and paclitaxel was given, but follow-up imaging iden-
tified continued disease progression and she remained
with a persistent continuous, offensive smelling vaginal
discharge requiring 7–8 pads daily and impacting her
quality of life.
Chemotherapy was stopped 4 months prior to the ab-
lation. Pre-HIFU treatment magnetic resonance imaging
measured the cervical mass at approximately 7 × 4 ×
4 cm, with invasion into adjacent fat planes and the
lower myometrium. A computed tomography scan iden-
tified intralesional gas; although, a fistulous connection
was ruled out on physical examination.
HIFU procedure
Fully informed, written consent was obtained prior to en-
rollment in this study. Under general anaesthetic, an
intracavitary-guided HIFU device (Sonablate® 500, Sonacare
Medical, Charlotte, NC, USA) currently utilised in the
treatment of prostatic malignancy was passed into the rec-
tum, as adequate alignment with the tumour could not be
obtained trans-vaginally. The tumour and surrounding
structures were visualised using integrated ultrasound im-
aging in sagittal and cross-axial planes, also providing treat-
ment monitoring. Intralesional gas obscured the majority
of the cranial portion of the lesion. Ultrasound energy can-
not penetrate air so HIFU was targeted to an approximately
4 × 4 × 1 cm region at the inferior margin, the most likely
area causing symptoms.
Hyperechoic greyscale changes and gas formation,
representing ablative effects [6], were visualised using the
real-time integrated ultrasound imaging to monitor for
the presence of tissue destruction (Fig. 1). Additional,
trans-abdominal ultrasound imaging was performed using
an iU22 (Philips Healthcare, Bothell, WA, USA) with a
curvilinear C5-1 transducer during treatment pauses for
monitoring targeting accuracy and treatment success. This
was used to supplement available trans-rectal imaging in
order to more closely observe the procedure. To minimise
potential toxicity, the lowest energy input required to
cause cell death was used during the procedure. This was
determined via integrated imaging, by monitoring for
hyperechoic changes. Tissue changes were observed with
output powers of 33 W/cm2 per individual foci, lower
than the 40 W/cm2 required for prostatic HIFU therapy.
Total treatment time was 40 min.
Post-procedure outcome
No intra- or immediate post-procedural adverse events
occurred. Upon waking from the anaesthetic, vaginal
bleeding and discharge had stopped completely. The pa-
tient was discharged home within 24 h of the procedure,
after a precautionary overnight stay to monitor for unex-
pected adverse events. She reported mild lower abdom-
inal pain after 48 h, which settled with simple analgesia
(1 g oral paracetamol, four times daily). At 7 days, vagi-
nal bleeding and discharge restarted at a lower volume
than in pre-treatment and reverted to pre-procedural
levels by 30 days. Baseline and post-therapy imaging is
shown in Fig. 2. Despite clinical benefit, there was no
significant reduction in lesion size following HIFU abla-
tion, although this was not unexpected as only a small
portion of the tumour was treated. The patient received
palliative therapy for symptomatic relief under the guid-
ance of the oncologists.
Discussion and evaluation
This first time experience of intracavitary cervical HIFU
suggests that it is feasible for palliation of advanced cer-
vical cancer, with no early evidence of unexpected tox-
icity. Rapid symptomatic benefit was achieved that has
improved the quality of life. In contrast to radiotherapy,
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HIFU offers the additional benefit of no dose ceiling,
allowing for repeated re-treatments if deemed appropri-
ate on an individual basis.
Ethical approval had also been granted for the use of per-
vaginal access if appropriate. Although considered for the
procedure, insertion of the transducer into the vagina did
not prove possible in this case. The device was not initially
intended for gynaecological use, and it proved impossible to
obtain satisfactory alignment to the target site as energy de-
livery is perpendicular to the transducer. This demonstrates
the need to have HIFU transducers specifically tailored to
individual indications. Alone or in combination with the
rectal route, this may provide increased accessibility in fu-
ture patients with a redesigned device more suited to trans-
vaginal ablations. Trans-vaginal ablations would also reduce
the risk of post-procedural fistulae when compared to the
trans-rectal approach, remove the possibility of skin burns
seen with trans-abdominal treatments and lower the poten-
tial for damage to the healthy intervening tissue, by short-
ening the distance to the tumour.
Fig. 2 Pre- and post-treatment MRI changes. Axial T2-weighted MRI at the level of the pelvic side wall showing the primary cervical tumour at
baseline (a) and post-treatment (b). A significant tumour burden remains, although, the AP length of the lesion has reduced in size from 4.5
to 3.4 cm
Fig. 1 Intraoperative tissue changes. Figure depicting intraoperative tissue changes identified using the integrated ultrasound imaging transducer
of the Sonablate® 500 HIFU device. Visualisation of hyperechoic transformation at the target site confirms tissue ablation. a Transverse and sagittal
still images of the cervical tumour depicting HIFU treatment planning. b Transverse and sagittal still images of the cervical tumour demonstrating
post-ablational hyperechoic effects, signifying effective ablation
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Conclusions
In conclusion, further detailed studies are now required to
fully assess safety and efficacy of HIFU, as well as dosimetry
and development of a dedicated cervical/gynaecological
probe design. As HIFU technology progresses, it could pro-
vide minimal toxicity with good relief of symptoms in pa-
tients who otherwise may have limited treatment options.
In the future, HIFU could also become an established part
of a multi-modal approach with curative intent in combin-
ation with current available therapy options to treat early
stages of cervical and other gynaecological cancers.
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